Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics
Covered in this story
What has happened since
- PTC Inc. is up 44.3% since this was published, 35 days ago.
- Ptc Therapeutics Inc is down 7.3% since this was published, 35 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on PTC Inc.
- BMO Capital Markets: $192 → $205 by Oct 2027 · Market Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PTC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on PTC Inc. →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.